Aktiesnakken — November 2009
-
er der nogle genmab drenge p ålinien??
-
har børsen fået det galt i halsen....er RITUX røget i 1st line CLL????
-
Er arzerra nu det eneste CD20 stof godkendt til CLL??? eller hvad??
-
det er da en information der er super vigtig!!!!
-
Børsen
Meget mere end Danmarks førende erhvervsavis. Børsen sætter dagsordenen for erhvervslivet. Vi skriver interessant og med kant. På alle platforme.
(borsen.dk)
-
den er da gået hen over hovedet på alle
-
det var åbenbart det complete svar som FDA gav roche igår!!!
-
ja men hvis roche har udtalt sig..så.....
-
men de kan vel for fanden da ikke opfinde et svar fra Roche
-
-
-
JA! men der er jo intet svar der....
-
minor setback, delays...
-
Carol Werther, an analyst with Summer Street Research, noted that Rituxan has been used for CLL for a very long time, and getting the approv
-
approval in that indication "is not going to change drug practice."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind